BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27005460)

  • 21. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes.
    Souli M; Galani I; Antoniadou A; Papadomichelakis E; Poulakou G; Panagea T; Vourli S; Zerva L; Armaganidis A; Kanellakopoulou K; Giamarellou H
    Clin Infect Dis; 2010 Feb; 50(3):364-73. PubMed ID: 20041768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series.
    Murri R; Fiori B; Spanu T; Mastrorosa I; Giovannenze F; Taccari F; Palazzolo C; Scoppettuolo G; Ventura G; Sanguinetti M; Cauda R; Fantoni M
    Infection; 2017 Apr; 45(2):209-213. PubMed ID: 28185222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias.
    Micozzi A; Gentile G; Minotti C; Cartoni C; Capria S; Ballarò D; Santilli S; Pacetti E; Grammatico S; Bucaneve G; Foà R
    BMC Infect Dis; 2017 Mar; 17(1):203. PubMed ID: 28283020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.
    Gutiérrez-Gutiérrez B; Salamanca E; de Cueto M; Hsueh PR; Viale P; Paño-Pardo JR; Venditti M; Tumbarello M; Daikos G; Cantón R; Doi Y; Tuon FF; Karaiskos I; Pérez-Nadales E; Schwaber MJ; Azap ÖK; Souli M; Roilides E; Pournaras S; Akova M; Pérez F; Bermejo J; Oliver A; Almela M; Lowman W; Almirante B; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J;
    Lancet Infect Dis; 2017 Jul; 17(7):726-734. PubMed ID: 28442293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae.
    Souli M; Karaiskos I; Masgala A; Galani L; Barmpouti E; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1305-1315. PubMed ID: 28210888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae.
    Falcone M; Bassetti M; Tiseo G; Giordano C; Nencini E; Russo A; Graziano E; Tagliaferri E; Leonildi A; Barnini S; Farcomeni A; Menichetti F
    Crit Care; 2020 Jan; 24(1):29. PubMed ID: 32000834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
    Mosqueda-Gómez JL; Montaño-Loza A; Rolón AL; Cervantes C; Bobadilla-del-Valle JM; Silva-Sánchez J; Garza-Ramos U; Villasís-Keever A; Galindo-Fraga A; Palacios GM; Ponce-de-León A; Sifuentes-Osornio J
    Int J Infect Dis; 2008 Nov; 12(6):653-9. PubMed ID: 18511321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective.
    Daikos GL; Markogiannakis A; Souli M; Tzouvelekis LS
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1393-404. PubMed ID: 23253318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.
    Tumbarello M; Spanu T; Sanguinetti M; Citton R; Montuori E; Leone F; Fadda G; Cauda R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):498-504. PubMed ID: 16436702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae.
    Wiskirchen DE; Crandon JL; Nicolau DP
    Int J Antimicrob Agents; 2013 Jun; 41(6):582-5. PubMed ID: 23611306
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics and outcome of patients with community-onset Klebsiella pneumoniae bacteremia requiring intensive care.
    Tseng CP; Wu HS; Wu TH; Lin YT; Fung CP
    J Microbiol Immunol Infect; 2013 Jun; 46(3):217-23. PubMed ID: 22832028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters.
    Cheng WL; Hsueh PR; Lee CC; Li CW; Li MJ; Chang CM; Lee NY; Ko WC
    J Microbiol Immunol Infect; 2016 Apr; 49(2):208-15. PubMed ID: 25070279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
    Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
    Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy.
    Brescini L; Morroni G; Valeriani C; Castelletti S; Mingoia M; Simoni S; Masucci A; Montalti R; Vivarelli M; Giacometti A; Barchiesi F
    BMC Infect Dis; 2019 Jul; 19(1):611. PubMed ID: 31299943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dissemination of extensively drug-resistant and KPC-2 producing Klebsiella pneumoniae isolated from bloodstream infections.
    Zhao F; Zhang J; Fu Y; Ruan Z; Xie X
    J Infect Dev Ctries; 2015 Sep; 9(9):1016-21. PubMed ID: 26409744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of NDM-1 Klebsiella pneumoniae bacteraemia in a neutropenic patient.
    Chien JM; Koh TH; Chan KS; Chuah TH; Tan TT
    Scand J Infect Dis; 2012 Apr; 44(4):312-4. PubMed ID: 22126430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum beta-lactamase.
    Peña C; Pujol M; Ardanuy C; Ricart A; Pallarés R; Liñares J; Ariza J; Gudiol F
    J Hosp Infect; 2001 Jan; 47(1):53-9. PubMed ID: 11161899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia.
    Chen CY; Tsay W; Tang JL; Tien HF; Chen YC; Chang SC; Hsueh PR
    Epidemiol Infect; 2010 Jul; 138(7):1044-51. PubMed ID: 19941686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient.
    Jacobs DM; DiTursi S; Ruh C; Sharma R; Claus J; Banjade R; Rao GG
    Int J Antimicrob Agents; 2016 Aug; 48(2):225-7. PubMed ID: 27396948
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.